drugset / Trial / NCT01521312

ACute and Chronic Effects of Saxagliptin

NCT01521312

Phase 2 Completed 24 enrolled Assistance Publique - Hôpitaux de Paris
RandomizedParallel-groupDouble-blindTreatment

Summary

Glucose ACCES study will explore the acute and long term (12-week treatment) effects of saxagliptin in patients with impaired glucose tolerance during fasting and after a standardised breakfast. The investigations will be performed on: * glycemic parameters * on cardiovascular parameters

Timeline

Start
2012-09
Primary completion
2014-09
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject SAXAGLIPTIN ANHYDROUS Small molecule 5 mg

Indications